JP6446355B2 - セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 - Google Patents

セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 Download PDF

Info

Publication number
JP6446355B2
JP6446355B2 JP2015507076A JP2015507076A JP6446355B2 JP 6446355 B2 JP6446355 B2 JP 6446355B2 JP 2015507076 A JP2015507076 A JP 2015507076A JP 2015507076 A JP2015507076 A JP 2015507076A JP 6446355 B2 JP6446355 B2 JP 6446355B2
Authority
JP
Japan
Prior art keywords
tmprss2
pharmaceutical composition
antibody
influenza virus
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015507076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516975A5 (enExample
JP2015516975A (ja
Inventor
ヌガンボ リサ・エー・パーセル
ヌガンボ リサ・エー・パーセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2015516975A publication Critical patent/JP2015516975A/ja
Publication of JP2015516975A5 publication Critical patent/JP2015516975A5/ja
Application granted granted Critical
Publication of JP6446355B2 publication Critical patent/JP6446355B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2015507076A 2012-04-16 2013-04-15 セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 Active JP6446355B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261624519P 2012-04-16 2012-04-16
US61/624,519 2012-04-16
US201361759469P 2013-02-01 2013-02-01
US61/759,469 2013-02-01
PCT/US2013/036522 WO2013158516A1 (en) 2012-04-16 2013-04-15 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017203146A Division JP2018048169A (ja) 2012-04-16 2017-10-20 セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法

Publications (3)

Publication Number Publication Date
JP2015516975A JP2015516975A (ja) 2015-06-18
JP2015516975A5 JP2015516975A5 (enExample) 2016-05-19
JP6446355B2 true JP6446355B2 (ja) 2018-12-26

Family

ID=48184523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015507076A Active JP6446355B2 (ja) 2012-04-16 2013-04-15 セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法
JP2017203146A Withdrawn JP2018048169A (ja) 2012-04-16 2017-10-20 セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017203146A Withdrawn JP2018048169A (ja) 2012-04-16 2017-10-20 セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法

Country Status (14)

Country Link
US (1) US9498529B2 (enExample)
EP (2) EP2838558A1 (enExample)
JP (2) JP6446355B2 (enExample)
KR (1) KR20150008383A (enExample)
CN (1) CN104244978A (enExample)
AU (2) AU2013249577A1 (enExample)
BR (1) BR112014025339A8 (enExample)
CA (2) CA2869010A1 (enExample)
HK (1) HK1202817A1 (enExample)
MX (1) MX2014012285A (enExample)
NZ (1) NZ631105A (enExample)
SG (1) SG11201405163RA (enExample)
WO (1) WO2013158516A1 (enExample)
ZA (1) ZA201406194B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017228293B2 (en) * 2016-02-29 2023-05-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized Tmprss gene
KR101693243B1 (ko) * 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
LT3638698T (lt) * 2018-01-26 2021-04-12 Regeneron Pharmaceuticals, Inc. Antikūnai prieš tmprss2 ir antigeną surišantys fragmentai
CN115427457A (zh) 2020-02-10 2022-12-02 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195119A1 (en) * 2020-03-24 2021-09-30 Corcept Therapeutics Incorporated Methods of reducing the risk of, severity of, and treating coronavirus infections
EP3964207A1 (en) 2020-09-02 2022-03-09 Christian-Albrechts-Universität zu Kiel Antiviral pharmaceutical composition for topical administration
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166194A (en) * 1998-06-29 2000-12-26 Myriad Genetics, Inc. TMPRSS2 is a tumor suppressor
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
KR101387781B1 (ko) * 2005-01-07 2014-04-21 렉시컨 파마슈티컬스 인코퍼레이티드 앤지오포이에틴-유사 단백질 4 (ａｎｇｐｔｌ４) 에 대한단일클론 항체
US20070191322A1 (en) 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Microbial Compositions and Methods of Use
JP2008247864A (ja) * 2007-03-30 2008-10-16 Univ Of Tokushima モザイクセリンプロテアーゼ、ｍｓｐとその用途
JP2008308438A (ja) * 2007-06-14 2008-12-25 Mitsubishi Tanabe Pharma Corp 新規なインフルエンザ治療および／または予防薬
BRPI1014745B1 (pt) 2009-06-22 2020-10-20 Borealis Ag artigo para interior de automóveis com odor reduzido
DK3702374T3 (da) * 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater

Also Published As

Publication number Publication date
AU2018200265B2 (en) 2019-07-18
HK1202817A1 (en) 2015-10-09
ZA201406194B (en) 2016-08-31
CN104244978A (zh) 2014-12-24
CA2869010A1 (en) 2013-10-24
AU2018200265A1 (en) 2018-02-01
CA3219083A1 (en) 2013-10-24
NZ631105A (en) 2016-09-30
EP3536342A1 (en) 2019-09-11
MX2014012285A (es) 2015-04-13
US9498529B2 (en) 2016-11-22
KR20150008383A (ko) 2015-01-22
AU2013249577A1 (en) 2014-10-02
EP2838558A1 (en) 2015-02-25
US20130273070A1 (en) 2013-10-17
JP2015516975A (ja) 2015-06-18
WO2013158516A1 (en) 2013-10-24
BR112014025339A2 (pt) 2013-10-24
BR112014025339A8 (pt) 2018-01-16
SG11201405163RA (en) 2014-09-26
JP2018048169A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
JP6446355B2 (ja) セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR102462039B1 (ko) Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
DK2892927T3 (en) METHODS OF TREATING ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
EP3515465B1 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
US20230102151A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
HK40014386A (en) Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
HK40010552B (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
HK40010552A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181203

R150 Certificate of patent or registration of utility model

Ref document number: 6446355

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250